You searched for "COVID"

1286 results found

Emerging therapies for geographic atrophy: complement inhibitors show potential to slow progression and preserve RPE and photoreceptor integrity

Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) characterised by progressive, irreversible loss of the retinal pigment epithelium (RPE) and photoreceptors and is estimated to account for approximately 10% of AMD-related blindness [1-4]. The Age-Related Eye...

Understanding and confronting bacterial endophthalmitis

Abdus Samad Ansari highlights the importance of early recognition of this condition using an unusual presentation. Endophthalmitis is a medical emergency with devastating consequences. Despite adequate treatment, severe cases frequently result in permanent blindness. Endophthalmitis involves inflammation of both the...

Diabetic Retinopathy Network laser training programme

The VISION 2020 Diabetic Retinopathy Network (DR-NET) was established in 2014 to tackle the increasing burden of diabetes and diabetic retinopathy (DR) in developing countries [1]. By forming a network of long-term LINK capacity-building partnerships, learning and best practice can...

Collaborating across the Caribbean to tackle diabetic retinopathy

The VISION 2020 LINKS Programme has been running since 2004, with a focus on improving the quality and quantity of eye care training in low-income countries [1]. In 2014, the Diabetic Retinopathy Network (DR-NET) was established [2]. This is a...

The Makassar-Dundee VISION 2020 LINK: a tale of two cities and two trainees

A resident’s view from Makassar My name is Hendra Kusuma, a final year resident (registrar) in the ophthalmology department at Hasanuddin University in Makassar, Indonesia. We have had a VISION 2020 LINK with Dundee (coordinated at the UK end by...

The invisible touch: a VISION 2020 LINK with Indonesia

Indonesia’s population, the world’s fourth largest, is spread across 6,000 inhabited islands. Whilst some areas (e.g. Kalimantan, Papua) are relatively sparsely populated, Java is the world’s most densely populated island, with twice the population of the UK in half the...

Post-stroke visual impairment: how big is the problem, how do we identify it, what we can do about it, and why does it matter?

In the UK, 100,000 new strokes occur each year, with 1.3 million stroke survivors [1]. This article will focus on post-stroke visual impairment, discussing topics of how common it is, how it can be detected, possible management options and how...

The VISION 2020 LINKS Programme: Cascading leadership training in Calabar, Nigeria

The VISION 2020 LINKS Programme has initiated ‘LEAD FORWARD’, an innovative leadership development project incorporating a commitment to cascade training and participate in achievable quality or service improvement projects. The project provides opportunities to apply leadership skills in practice as...

Sustainability in eyecare: Climate action in eyecare

Climate change will cause disruption to critical eyecare services and increases in rates of eye disease around the world. The International Agency for Prevention of Blindness has recommended 10 key areas of action on how the eyecare sector can address...

More sensitive visual acuity test for age-related macular degeneration

Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world. Primarily associated with ageing, genetic factors and lifestyle choices such as smoking also play a contributory role. Patients with early AMD, characterised by the development of...

Surgical options for the treatment of hyperopia

The modern refractive surgeon has a variety of options available to treat patients with hyperopia who wish to be independent of spectacles and contact lenses. Unlike in low myopia where presbyopic patients may have the ability to see well for...

Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice

The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...